Futura Medical hails positive regulatory momentum

0
7
  • Futura Medical inks deal that will take its erectile dysfunction gel to Brazil and Mexico
  • How Futura Medical turned MED3000 into a near-billion pound opportunity
  • Futura Medical: More deals will follow after LatAm agreement, says City broker
  • Futura Medical reaches licensing deal for erectile dysfunction gel in Brazil and Mexico
Futura Medical PLC -

Quick facts: Futura Medical PLC

Follow

View company profile

Futura Medical PLC is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys technology.

Each DermaSys formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience.

The products are developed for the prescription and consumer healthcare markets as appropriate.

Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief.

31 Aug 2021

() () has inked a licensing deal which should see its fast-acting erectile dysfunction gel rolled out across Brazil and Mexico.

It said it will receive payments on all sales of its MED3000 treatment by m8 Pharmaceuticals.

The announcement reveals the UK group, which is also developing a pain relief drug using its transdermal technology, will receive milestone payments of US$8.5mln.

These will be based on “deliverable sales volumes”, while Futura will also receive a small upfront sum.

Read more

19 Jul 2021

() said it enjoyed a positive interaction with the US drug regulator which should pave the way for its erectile dysfunction gel to be sold over the counter.

The Food & Drug Administration has agreed the design of a non-clinical human factors study, which will assess the ability of men to self-diagnose and correctly select the product without a doctor’s supervision.

Read more

28 Jun 2021

Discussions with companies interested in licensing ‘s () breakthrough erectile dysfunction gel are ongoing, investors will be told at Monday’s annual meeting.

The company has already brokered deals covering China and south-east Asia for MED3000.

Read more

14 Apr 2021

When life gives you lemons, make lemonade, say many people on the internet.

That’s one way to describe what () has done with MED3000, its candidate for erectile dysfunction (ED).

Read more

31 Aug 2021

More deals will come for (), which earlier on Tuesday said it had inked an agreement to commercialise its fast-acting erectile dysfunction (ED) gel in Brazil and Mexico.

That at least is the opinion of City broker Liberum, which reiterated its ‘buy’ recommendation and 102p a share price target following the tie-up with m8 Pharmaceuticals.

“Futura is talking to many more potential partners as it works to build the global commercialisation landscape, and we expect more licensing agreements to be signed in the coming months,” said Liberum in a note to clients.

Read more

31 Aug 2021

() chief executive James Barder joined Proactive’s Stephen Gunnion with news of a licensing deal which should see its fast-acting erectile dysfunction gel introduced to Brazil and Mexico.

Barder telling Proactive that it will receive payments on all sales of its MED3000 treatment by m8 Pharmaceuticals.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Futura Medical reaches licensing deal for erectile dysfunction gel in Brazil…

Futura Medical PLC (AIM:FUM) chief executive James Barder joined Proactive’s Stephen Gunnion with news of a licensing deal which should see its fast-acting erectile dysfunction gel introduced to Brazil and Mexico.

Barder telling Proactive that it will receive payments on all sales of its…

6 hours, 57 minutes ago

4 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here